# Okta, Inc.: financial statements, quarterly

OKTA · Nasdaq · CIK 1660134 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/okta.md) · [Financials](/companies/okta/financials.md) · [Filings](/companies/okta/filings.md) · [Insiders](/companies/okta/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/okta/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [584](/filings/0001660134-24-000168.md) | [605 d](/filings/0001660134-26-000020.md) | [617](/filings/0001660134-25-000093.md) | [646](/filings/0001660134-25-000157.md) | [665](/filings/0001660134-25-000171.md) | [682 d](/filings/0001660134-26-000020.md) | [688](/filings/0001660134-26-000051.md) | [728](/filings/0001660134-26-000069.md) | [742](/filings/0001660134-25-000171.md) | [761 d](/filings/0001660134-26-000020.md) | [765](/filings/0001660134-26-000051.md) | [805](/filings/0001660134-26-000069.md) |
| Cost of revenue | $m | [145](/filings/0001660134-24-000168.md) | [145 d](/filings/0001660134-26-000020.md) | [148](/filings/0001660134-25-000093.md) | [155](/filings/0001660134-25-000157.md) | [157](/filings/0001660134-25-000171.md) | [158 d](/filings/0001660134-26-000020.md) | [155](/filings/0001660134-26-000051.md) | [168](/filings/0001660134-26-000069.md) | [170](/filings/0001660134-25-000171.md) | [168 d](/filings/0001660134-26-000020.md) | [170](/filings/0001660134-26-000051.md) | [164](/filings/0001660134-26-000069.md) |
| Gross profit | $m | [439](/filings/0001660134-24-000168.md) | [460 d](/filings/0001660134-26-000020.md) | [469](/filings/0001660134-25-000093.md) | [491](/filings/0001660134-25-000157.md) | [508](/filings/0001660134-25-000171.md) | [524 d](/filings/0001660134-26-000020.md) | [533](/filings/0001660134-26-000051.md) | [560](/filings/0001660134-26-000069.md) | [572](/filings/0001660134-25-000171.md) | [593 d](/filings/0001660134-26-000020.md) | [595](/filings/0001660134-26-000051.md) | [641](/filings/0001660134-26-000069.md) |
| Research and development | $m | [165](/filings/0001660134-24-000168.md) | [156 d](/filings/0001660134-26-000020.md) | [163](/filings/0001660134-25-000093.md) | [164](/filings/0001660134-25-000157.md) | [158](/filings/0001660134-25-000171.md) | [157 d](/filings/0001660134-26-000020.md) | [154](/filings/0001660134-26-000051.md) | [160](/filings/0001660134-26-000069.md) | [160](/filings/0001660134-25-000171.md) | [165 d](/filings/0001660134-26-000020.md) | [163](/filings/0001660134-26-000051.md) | [163](/filings/0001660134-26-000069.md) |
| Operating income | $m | [(111)](/filings/0001660134-24-000168.md) | [(83.0) d](/filings/0001660134-26-000020.md) | [(47.0)](/filings/0001660134-25-000093.md) | [(19.0)](/filings/0001660134-25-000157.md) | [(16.0)](/filings/0001660134-25-000171.md) | [8.0 d](/filings/0001660134-26-000020.md) | [39.0](/filings/0001660134-26-000051.md) | [41.0](/filings/0001660134-26-000069.md) | [23.0](/filings/0001660134-25-000171.md) | [46.0 d](/filings/0001660134-26-000020.md) | [56.0](/filings/0001660134-26-000051.md) | [107](/filings/0001660134-26-000069.md) |
| Interest expense | $m | [2.0](/filings/0001660134-23-000068.md) | [1.0 d](/filings/0001660134-24-000025.md) | [2.0](/filings/0001660134-24-000088.md) | [1.0](/filings/0001660134-25-000157.md) | [1.0](/filings/0001660134-25-000171.md) | [1.0 d](/filings/0001660134-26-000020.md) | [1.0](/filings/0001660134-26-000051.md) | [1.0](/filings/0001660134-26-000069.md) | [1.0](/filings/0001660134-25-000171.md) | [1.0 d](/filings/0001660134-26-000020.md) | [1.0](/filings/0001660134-26-000051.md) | [0.0](/filings/0001660134-26-000069.md) |
| Income tax | $m | [7.0](/filings/0001660134-24-000168.md) | [0.0 d](/filings/0001660134-26-000020.md) | [18.0](/filings/0001660134-25-000093.md) | [(17.0)](/filings/0001660134-25-000157.md) | [9.0](/filings/0001660134-25-000171.md) | [8.0 d](/filings/0001660134-26-000020.md) | [6.0](/filings/0001660134-26-000051.md) | [0.0](/filings/0001660134-26-000069.md) | [7.0](/filings/0001660134-25-000171.md) | [7.0 d](/filings/0001660134-26-000020.md) | [4.0](/filings/0001660134-26-000051.md) | [10.0](/filings/0001660134-26-000069.md) |
| Net income | $m | [(81.0)](/filings/0001660134-24-000168.md) | [(44.0) d](/filings/0001660134-26-000020.md) | [(40.0)](/filings/0001660134-25-000171.md) | [29.0](/filings/0001660134-25-000171.md) | [16.0](/filings/0001660134-25-000171.md) | [23.0 d](/filings/0001660134-26-000020.md) | [62.0](/filings/0001660134-26-000069.md) | [67.0](/filings/0001660134-26-000069.md) | [43.0](/filings/0001660134-25-000171.md) | [63.0 d](/filings/0001660134-26-000020.md) | [74.0](/filings/0001660134-26-000069.md) | [116](/filings/0001660134-26-000069.md) |
| Diluted EPS | $ per share | [(0.49)](/filings/0001660134-24-000168.md) | not reported | [(0.24)](/filings/0001660134-25-000093.md) | [0.15](/filings/0001660134-25-000157.md) | [0.00](/filings/0001660134-25-000171.md) | not reported | [0.35](/filings/0001660134-26-000051.md) | [0.37](/filings/0001660134-26-000069.md) | [0.24](/filings/0001660134-25-000171.md) | not reported | [0.42](/filings/0001660134-26-000051.md) | [0.65](/filings/0001660134-26-000069.md) |
| Basic EPS | $ per share | [(0.49)](/filings/0001660134-24-000168.md) | not reported | [(0.24)](/filings/0001660134-25-000093.md) | [0.18](/filings/0001660134-25-000157.md) | [0.09](/filings/0001660134-25-000171.md) | not reported | [0.36](/filings/0001660134-26-000051.md) | [0.38](/filings/0001660134-26-000069.md) | [0.24](/filings/0001660134-25-000171.md) | not reported | [0.42](/filings/0001660134-26-000051.md) | [0.67](/filings/0001660134-26-000069.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [400](/filings/0001660134-24-000168.md) | [334](/filings/0001660134-26-000020.md) | [322](/filings/0001660134-25-000093.md) | [515](/filings/0001660134-25-000157.md) | [310](/filings/0001660134-25-000171.md) | [409](/filings/0001660134-26-000020.md) | [494](/filings/0001660134-26-000051.md) | [876](/filings/0001660134-26-000069.md) | [645](/filings/0001660134-25-000171.md) | [858](/filings/0001660134-26-000069.md) | [762](/filings/0001660134-26-000051.md) | [763](/filings/0001660134-26-000069.md) |
| Current assets | $m | [2,727](/filings/0001660134-23-000068.md) | [2,980](/filings/0001660134-25-000049.md) | [2,917](/filings/0001660134-24-000088.md) | [3,038](/filings/0001660134-24-000138.md) | [3,003](/filings/0001660134-24-000168.md) | [3,416](/filings/0001660134-26-000020.md) | [3,365](/filings/0001660134-25-000093.md) | [3,566](/filings/0001660134-25-000157.md) | [3,201](/filings/0001660134-25-000171.md) | [3,644](/filings/0001660134-26-000069.md) | [3,306](/filings/0001660134-26-000051.md) | [3,089](/filings/0001660134-26-000069.md) |
| Total assets | $m | [8,740](/filings/0001660134-23-000068.md) | [8,989](/filings/0001660134-25-000049.md) | [8,955](/filings/0001660134-24-000088.md) | [9,067](/filings/0001660134-24-000138.md) | [9,010](/filings/0001660134-24-000168.md) | [9,437](/filings/0001660134-26-000020.md) | [9,365](/filings/0001660134-25-000093.md) | [9,550](/filings/0001660134-25-000157.md) | [9,229](/filings/0001660134-25-000171.md) | [9,710](/filings/0001660134-26-000069.md) | [9,347](/filings/0001660134-26-000051.md) | [9,138](/filings/0001660134-26-000069.md) |
| Current liabilities | $m | [1,543](/filings/0001660134-23-000068.md) | [1,782](/filings/0001660134-25-000049.md) | [1,686](/filings/0001660134-24-000088.md) | [1,660](/filings/0001660134-24-000138.md) | [2,234](/filings/0001660134-24-000168.md) | [2,523](/filings/0001660134-26-000020.md) | [2,296](/filings/0001660134-25-000093.md) | [2,647](/filings/0001660134-25-000157.md) | [2,184](/filings/0001660134-25-000171.md) | [2,554](/filings/0001660134-26-000069.md) | [2,312](/filings/0001660134-26-000051.md) | [2,025](/filings/0001660134-26-000069.md) |
| Total liabilities | $m | [3,010](/filings/0001660134-23-000068.md) | [3,101](/filings/0001660134-25-000049.md) | [3,002](/filings/0001660134-24-000088.md) | [2,934](/filings/0001660134-24-000138.md) | [2,745](/filings/0001660134-24-000168.md) | [3,032](/filings/0001660134-26-000020.md) | [2,798](/filings/0001660134-25-000093.md) | [2,796](/filings/0001660134-25-000157.md) | [2,336](/filings/0001660134-25-000171.md) | [2,711](/filings/0001660134-26-000069.md) | [2,448](/filings/0001660134-26-000051.md) | [2,165](/filings/0001660134-26-000069.md) |
| Shareholders' equity | $m | [5,730](/filings/0001660134-24-000168.md) | [5,888](/filings/0001660134-26-000020.md) | [5,953](/filings/0001660134-25-000171.md) | [6,133](/filings/0001660134-25-000171.md) | [6,265](/filings/0001660134-25-000171.md) | [6,405](/filings/0001660134-26-000069.md) | [6,567](/filings/0001660134-26-000069.md) | [6,754](/filings/0001660134-26-000069.md) | [6,893](/filings/0001660134-25-000171.md) | [6,999](/filings/0001660134-26-000069.md) | [6,899](/filings/0001660134-26-000069.md) | [6,973](/filings/0001660134-26-000069.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [156 d](/filings/0001660134-24-000168.md) | [174 d](/filings/0001660134-26-000020.md) | [219](/filings/0001660134-25-000093.md) | [86.0 d](/filings/0001660134-25-000157.md) | [159 d](/filings/0001660134-25-000171.md) | [286 d](/filings/0001660134-26-000020.md) | [241](/filings/0001660134-26-000051.md) | [167 d](/filings/0001660134-26-000069.md) | [218 d](/filings/0001660134-25-000171.md) | [258 d](/filings/0001660134-26-000020.md) | [277](/filings/0001660134-26-000051.md) | [234 d](/filings/0001660134-26-000069.md) |
| Capital expenditure | $m | [3.0 d](/filings/0001660134-24-000168.md) | [3.0 d](/filings/0001660134-26-000020.md) | [1.0](/filings/0001660134-25-000093.md) | [5.0 d](/filings/0001660134-25-000157.md) | [1.0 d](/filings/0001660134-25-000171.md) | [1.0 d](/filings/0001660134-26-000020.md) | [1.0](/filings/0001660134-26-000051.md) | [2.0 d](/filings/0001660134-26-000069.md) | [4.0 d](/filings/0001660134-25-000171.md) | [2.0 d](/filings/0001660134-26-000020.md) | [1.0](/filings/0001660134-26-000051.md) | [1.0 d](/filings/0001660134-26-000069.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001660134-26-000051.md) | [0.0 d](/filings/0001660134-26-000069.md) | not reported | not reported | [248](/filings/0001660134-26-000051.md) | [124 d](/filings/0001660134-26-000069.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [159](/filings/0001660134-23-000068.md) | [161](/filings/0001660134-24-000088.md) | [163](/filings/0001660134-24-000138.md) | [164](/filings/0001660134-24-000168.md) | [167](/filings/0001660134-25-000093.md) | [174](/filings/0001660134-25-000157.md) | [171](/filings/0001660134-25-000171.md) | [182](/filings/0001660134-26-000051.md) | [181](/filings/0001660134-26-000069.md) | [178](/filings/0001660134-25-000171.md) | [178](/filings/0001660134-26-000051.md) | [179](/filings/0001660134-26-000069.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.